Union Life

Union Therapeutics is a clinical-stage pharmaceutical company focused on developing novel treatments for inflammatory and infectious diseases. The company leverages a strategy of reformulating and repurposing well-characterized molecules to address significant unmet medical needs. Its lead candidate, oritavancin (UNI-001), is being investigated for various skin infections, while UNI-494 is in development for inflammatory conditions like atopic dermatitis. Union Therapeutics also gained prominence for its work on niclosamide-based therapies (UNI-500) for respiratory viral infections, including COVID-19. The company aims to provide safer and more effective therapeutic options through innovative delivery and formulation technologies.